The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic—an effective antiviral that has since successfully treated millions. But like many antivirals before it, ...
5don MSN
Small-molecule antiviral drug targets ACE2 receptor to block coronaviruses from entering cells
The ongoing evolution of SARS-CoV-2, particularly the rapid emergence of the omicron variant and its sublineages, has ...
A University of Alberta research team has uncovered a new class of drugs with the potential to prevent or treat infections in a future viral outbreak. In the paper, published this week in Nature, the ...
Viral genome sequencing provides valuable information for antiviral development, yet its integration with machine learning for virtual screening remains underexplored. To bridge this gap, viral genome ...
The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions. But like many antivirals before it ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...
SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its ...
Can newly identified antiviral compounds help stop some of the most dangerous mosquito-borne viruses that attack the brain? A ...
(NYSE American:NNVC, opens new tab) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot ...
Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results